Zhongsheng pharmaceutical and Wuxi apptec sign two more technology development contracts

Abstract: on July 13, 2015, Zhongsheng Pharmaceutical Co., Ltd and Wuxi apptec signed the strategic cooperation agreement between Guangdong Zhongsheng Pharmaceutical Co., Ltd and Shanghai apptec new drug development Co., Ltd According to the strategic cooperation agreement signed by the company and Wuxi apptec, the two sides will implement and sign more than two cooperation projects in the second half of 2015 Following the cooperation between the company and Wuxi apptec on zsym001, zsym002 and zsym003 projects, the signing of this technology development (cooperation) contract is the specific implementation of the company's and Wuxi apptec's strategic cooperation ideas and ideas, is another sign of the promotion and implementation of the strategic agreement between the two sides, and further lays the foundation for the implementation of the strategic cooperation between the two sides At the same time, the implementation of the project will enrich the company's new drug R & D reserves, lay a solid foundation for the company's innovation and development, further enhance the company's overall strength and market competitive advantage, and enhance the company's future profitability This announcement is interpreted as generally good At present, the company's main product sales are stable In the early stage, the company merged and acquired Xianqiang pharmaceutical to expand its product line, increase its performance flexibility, cooperate with Xinglin, actively arrange the Internet plus, and cooperate with Shanghai yaomingkant, laying a foundation for the company's long-term development Attached with the summary of announcement, Zhongsheng pharmaceutical announced on October 13, 2015 that the company had recently received the approval document for drug supplement application approved and issued by Guangdong food and drug administration, with the approval number of Guangdong b201500323, the drug name of adenosine triphosphate disodium chloride for injection, the drug approval number of Guoyao Zhunzi h20158003, and the validity period of the drug approval number of until October 7, 2020 Announcement I of Zhongsheng pharmaceutical on October 9, 2015 overview of contract signing Guangdong Zhongsheng pharmaceutical On July 13, 2015, the 20th meeting of the 5th board of directors of Guangdong Zhongsheng Pharmaceutical Co., Ltd (hereinafter referred to as "the company") reviewed and passed the proposal on signing strategic cooperation agreement between Guangdong Zhongsheng Pharmaceutical Co., Ltd and Shanghai yaomingkant new drug development Co., Ltd., and agreed to sign a war between the company and Shanghai yaomingkant new drug development Co., Ltd (hereinafter referred to as "yaomingkant") Slightly cooperation agreement On July 13, 2015, the company and Wuxi apptec signed the strategic cooperation agreement between Guangdong Zhongsheng Pharmaceutical Co., Ltd and Shanghai apptec new drug development Co., Ltd According to the strategic cooperation agreement signed by the company and Wuxi apptec, the two sides will implement and sign more than two cooperation projects in the second half of 2015 The company and Wuxi apptec further promoted the implementation of the strategic cooperation agreement, and signed the technology development (cooperation) contract of zsym003, a new drug for the treatment of drug-resistant lung cancer, in August 2015 For details, please refer to the technical development (cooperation) signed between the company and Shanghai apptec new drug development Co., Ltd in the securities times on August 19, 2015 and disclosed by cninfo.com Announcement of the contract Recently, the company has signed the technology development (cooperation) contract (hereinafter referred to as the "contract") for zsym004, a new drug for tumor treatment 2 Main content of the contract (1) research and development of zsym004, a new class I new drug for tumor treatment (II) cooperation content In accordance with the technical requirements of chemical drug registration classification 1.1 in the measures for the administration of drug registration and the guiding principles of the drug evaluation center of the State Food and Drug Administration (CFDA), zsym004's preclinical pharmaceutical research, pharmacological and toxicological research, pilot scale-up and production process validation were completed, and the CFDA was applied for and the phase I clinical trial approval was obtained (III) project equity distribution 1 Both parties agree that the project adopts the mode of risk sharing and revenue sharing for R & D cooperation 2 For the preclinical candidate compounds (PCC) and clinical candidate compounds (ind) finally selected by the project committee, if both parties agree to transfer the project or international rights and interests to a third party in the preclinical phase, the transfer proceeds shall be distributed according to the contract 3 The company has the right to decide whether the project will enter into clinical and later stage research After the project enters into clinical stage, the cooperation mode will be determined separately After the project enters the clinical stage, the research work is led by the company, and the research funds are also provided by the company The rights and interests of Wuxi apptec in the final listed products shall be distributed according to the contract 4 The company has the right to decide to transfer preclinical candidate compounds (PCC) and clinical candidate compounds (ind) designed and mainly researched by Wuxi apptec The transfer proceeds shall be distributed according to the contract 5 The intellectual property rights, application materials and original test records of the project shall be owned by the company, and Wuxi apptec shall enjoy the income right of the research and development achievements of the project in accordance with the proportion agreed in the contract （4） Expenses and payment method: the company shall contribute 27 million yuan (excluding clinical research expenses) according to the contract, and pay in installments according to the plan agreed in the contract III Influence on the company after the company and Wuxi apptec cooperated on zsym001, zsym002 and zsym003 projects, the signing of this technology development (cooperation) contract is the specific implementation of the company's and Wuxi apptec's strategic cooperation ideas and ideas, is another sign of the promotion and implementation of the strategic agreement between the two sides, and further lays the foundation for the implementation of the strategic cooperation between the two sides At the same time, the implementation of the project will enrich the company's new drug R & D reserves, lay a solid foundation for the company's innovation and development, further enhance the company's overall strength and market competitive advantage, and enhance the company's future profitability, which is in line with the interests of all shareholders and the company's development strategy IV risk reminder (I) the technology development (cooperation) contract signed this time involves the development of innovative drugs Based on the characteristics of long cycle, high risk and high investment in new drug development, there is uncertainty in project promotion (II) the signing of this technology development (cooperation) contract does not have a significant impact on the company's short-term financial situation and operating results (III) the company will perform the obligation of information disclosure in accordance with the relevant provisions The information disclosure media designated by the company are securities times and cninfo.com.cn All information of the company is subject to the information published in the above selected media Please pay attention to relevant announcements and investment risks